organization · Reporting owner
Foresite Capital Fund I, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date May 12, 2020 · Filed May 14, 2020
Jointly reported with Foresite Capital Management I, LLC, Foresite Capital Management II, LLC, Foresite Capital Fund II, L.P., Tananbaum James B.
Section 16 reporting ended · disclosed 2020-05-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,300,000 |
Reported balance
After 2020-05-12 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-05-12 · Conversion · Acquired 1,930,198 · Balance 4,300,000 F1: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,500,000 |
Reported balance
After 2020-05-13 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-05-13 · Sale · Disposed 800,000 · Balance 3,500,000 F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,350,000 |
Reported balance
After 2020-05-13 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2020-05-13 · Sale · Disposed 650,000 · Balance 2,350,000 F3: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 327,383 |
Reported balance
Holding disclosure · report date 2020-05-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 327,383 F4: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2020-05-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-05-12 · Conversion · Disposed 1,930,198 · Balance 0 F1: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5: The Class B Common Stock has no expiration date. F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 3,153,528 |
Reported balance
Holding disclosure · report date 2020-05-12 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 3,153,528 F1: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5: The Class B Common Stock has no expiration date. F3: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election.
F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F4: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein.
F5: The Class B Common Stock has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2020 Filed May 14, 2020 18:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 650,000 | $80.13 | $52,084,500.00 |
DisclosureSEC source: 0000899243-20-013113 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,350,000 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 13, 2020 Filed May 14, 2020 18:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800,000 | $80.13 | $64,104,000.00 |
DisclosureSEC source: 0000899243-20-013113 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,500,000 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 12, 2020 Filed May 14, 2020 18:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,930,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-013113 · doc4.xml · derivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 1,930,198 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5 · derivative.expiration_date: The Class B Common Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 12, 2020 Filed May 14, 2020 18:01 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,930,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-013113 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,300,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 08:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012367 · doc4.xml · derivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,153,528 Underlying: Class A Common Stock · 1,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5 · derivative.expiration_date: The Class B Common Stock has no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 08:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012367 · doc4.xml · derivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,930,198 Underlying: Class A Common Stock · 500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5 · derivative.expiration_date: The Class B Common Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 08:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012367 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| May 06, 2020 Filed May 8, 2020 08:39 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012367 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,369,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · derivative · entry 7 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,430,198 Underlying: Class A Common Stock · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F8 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F8 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F10 · derivative.expiration_date: The Class B Common Stock has no expiration date. F1 · ownership.nature: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. Read SEC document |
| April 23, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,869,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 92,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 327,383 F6 · kind: The shares were obtained pursuant to a pro rata distribution from FCM I, for no consideration. F6 · price: The shares were obtained pursuant to a pro rata distribution from FCM I, for no consideration. F7 · ownership.nature: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 178,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F5 · kind: The shares were distributed on a pro rata basis by FCM I, for no consideration. F5 · price: The shares were distributed on a pro rata basis by FCM I, for no consideration. F4 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 178,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 178,584 F3 · kind: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F3 · price: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F4 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 700,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-011300 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 869,802 F1 · kind: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. F1 · price: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · derivative · entry 9 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,653,528 Underlying: Class A Common Stock · 1,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F13 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F13 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F14 · derivative.expiration_date: The Class B Common Stock has no expiration date. F4 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 8 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,500,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F4 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 109,849 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 7 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 235,125 F11 · kind: The shares represent (i) 105,367 shares obtained pursuant to a pro rata distribution from FCM I, for no consideration and (ii) 4,482 shares obtained pursuant to a pro rata distribution from FCM II, for no consideration. F11 · price: The shares represent (i) 105,367 shares obtained pursuant to a pro rata distribution from FCM I, for no consideration and (ii) 4,482 shares obtained pursuant to a pro rata distribution from FCM II, for no consideration. F12 · ownership.nature: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 21,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 6 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F10 · kind: The shares were distributed on a pro rata basis by FCM II, for no consideration. F10 · price: The shares were distributed on a pro rata basis by FCM II, for no consideration. F9 · ownership.nature: The shares are owned by FCM II the general partner of FCF II and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 21,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 21,686 F8 · kind: The shares were obtained pursuant to a pro rata distribution from FCF II, for no consideration. F8 · price: The shares were obtained pursuant to a pro rata distribution from FCF II, for no consideration. F9 · ownership.nature: The shares are owned by FCM II the general partner of FCF II and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 201,115 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F7 · kind: The shares were distributed on a pro rata basis by FCM I, for no consideration. F7 · price: The shares were distributed on a pro rata basis by FCM I, for no consideration. F6 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 201,115 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 201,115 F5 · kind: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F5 · price: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F6 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 433,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: The shares were distributed on a pro rata basis by FCF II (defined below), for no consideration. F3 · price: The shares were distributed on a pro rata basis by FCF II (defined below), for no consideration. F4 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 17:00 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 788,317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-010769 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,569,802 F1 · kind: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. F1 · price: The shares were distributed on a pro rata basis by FCF I (defined below), for no consideration. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 2,170,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009578 · doc4.xml · derivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,430,198 Underlying: Class A Common Stock · 2,170,619 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F5 · derivative.expiration_date: The Class B Common Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 2,170,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009578 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,358,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 125,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 8 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 125,276 F8 · kind: The shares were obtained pursuant to a pro rata distribution from FCM I, for no consideration. F8 · price: The shares were obtained pursuant to a pro rata distribution from FCM I, for no consideration. F9 · ownership.nature: The shares are owned by James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust ("Trust") of which Mr. Tananbaum is the trustee. Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 241,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 7 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F7 · kind: The shares were distributed on a pro rata basis by FCM I, for no consideration. F7 · price: The shares were distributed on a pro rata basis by FCM I, for no consideration. F6 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 241,619 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 6 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 241,619 F5 · kind: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F5 · price: The shares were obtained pursuant to a pro rata distribution from FCF I, for no consideration. F6 · ownership.nature: The shares are owned by FCM I the general partner of FCF I and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock | 947,079 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 187,500 F4 · kind: The shares were distributed on a pro rata basis by FCF I, for no consideration. F4 · price: The shares were distributed on a pro rata basis by FCF I, for no consideration. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 250,000 | $59.00 | $14,750,000.00 |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 433,725 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500,000 | $59.00 | $29,500,000.00 |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,134,579 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 04, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 683,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · derivative · entry 10 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,153,528 Underlying: Class A Common Stock · 683,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F10 · derivative.expiration_date: The Class B Common Stock has no expiration date. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 04, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 1,447,079 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · derivative · entry 9 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,600,817 Underlying: Class A Common Stock · 1,447,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F10 · derivative.expiration_date: The Class B Common Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 04, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 683,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 683,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| March 04, 2020 Filed Mar 19, 2020 17:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass A Common Stock | 1,447,079 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-009021 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,634,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 17:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 6,837,253 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049680 · doc4.xml · derivative · entry 8 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,837,253 Underlying: Class A Common Stock · 6,837,253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F13 · price: Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F10 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F11 · derivative.expiration_date: The Class B Common Stock has no expiration date. F9 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 17:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionClass B Common Stock · Derivative | 7,047,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049680 · doc4.xml · derivative · entry 7 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,047,896 Underlying: Class A Common Stock · 7,047,896 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F12 · price: Each share of Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F10 · derivative.exercise_date: Each share of Class B Common Stock is convertible, for no additional consideration, into one (1) share of Class A Common Stock at any time at the holder's election. F11 · derivative.expiration_date: The Class B Common Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 17:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,324,195 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049680 · doc4.xml · derivative · entry 6 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class B Common Stock · 1,324,195 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series C Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: The Series C Convertible Preferred Stock has no expiration date. F9 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 17:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionSeries B Convertible Preferred Stock · Derivative | 5,513,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049680 · doc4.xml · derivative · entry 5 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class B Common Stock · 5,513,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series B Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F6 · derivative.expiration_date: The Series B Convertible Preferred Stock has no expiration date. F9 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 17:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionSeries C Convertible Preferred Stock · Derivative | 558,260 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049680 · doc4.xml · derivative · entry 4 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class B Common Stock · 558,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series C Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: The Series C Convertible Preferred Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 17:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,002,166 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049680 · doc4.xml · derivative · entry 3 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class B Common Stock · 1,002,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series B Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F6 · derivative.expiration_date: The Series B Convertible Preferred Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 17:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 5,487,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-049680 · doc4.xml · derivative · entry 2 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Class B Common Stock · 5,487,470 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series A-2 Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F3 · price: Each share of Series A-2 Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Each share of Series A-2 Convertible Preferred Stock automatically converted, for no additional consideration, into one (1) share of Issuer's Class B Common Stock upon the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: The Series A-2 Convertible Preferred Stock has no expiration date. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 17:26 UTC | 10x Genomics, Inc. TXG · Entity 2172 | PurchaseClass A Common Stock | 187,500 | $39.00 | $7,312,500.00 |
DisclosureSEC source: 0001209191-19-049680 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management I, LLC · CIK 0001581219 · 10% owner Foresite Capital Fund I, L.P. · CIK 0001562157 · 10% owner Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 187,500 F1 · kind: FCF I purchased 187,500 shares of Issuer's Class A Common Stock in connection with the Issuer's initial public offering at the offering price of $39.00 per share. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.